Free tool
Stocks above their 200-day average
We cover 210 companies trading above their own 200-day average. The median market value in the group is $4.28B. Across the group, the median move over the past trading day is −0.07%. 100% of the 210 with a 200-day average trade above it. Price change over the past year runs from −9.6% to +256.1% across the middle 80 percent of the group, with a median of +49.0%. Across the group, 3 companies currently carry a tier A volume signal.
Other lists in this group
Table
210 of 10,735 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| LILY34.SA | Eli Lilly and Company | $1.10T | Mega cap | +59.83% |
| LLY.DE | Eli Lilly and Company | $1.07T | Mega cap | +73.55% |
| LLY | Eli Lilly and Company | $1.06T | Mega cap | +62.80% |
| JNJ | Johnson & Johnson | $658.24B | Mega cap | +55.40% |
| JNJB34.SA | Johnson & Johnson | $658.09B | Mega cap | +47.82% |
| JNJ.DE | Johnson & Johnson | $651.71B | Mega cap | +58.93% |
| 4AB.DE | AbbVie Inc. | $471.29B | Mega cap | +32.34% |
| ABBV | AbbVie Inc. | $469.68B | Mega cap | +29.36% |
| ABBV34.SA | AbbVie Inc. | $467.00B | Mega cap | +21.88% |
| MRCK34.SA | Merck & Co., Inc. | $388.60B | Mega cap | +81.07% |
| 6MK.DE | Merck & Co., Inc. | $379.64B | Mega cap | +91.49% |
| MRK | Merck & Co., Inc. | $377.72B | Mega cap | +86.85% |
| RHO.DE | Roche Holding AG | $370.84B | Mega cap | +41.42% |
| N1VS34.SA | Novartis AG | $301.83B | Mega cap | +20.04% |
| NOT.DE | Novartis AG | $300.14B | Mega cap | +28.89% |
| NVS | Novartis AG | $299.44B | Mega cap | +27.93% |
| AMGN34.SA | Amgen Inc. | $239.09B | Mega cap | +47.79% |
| AMGN | Amgen Inc. | $238.06B | Mega cap | +56.24% |
| AMG.DE | Amgen Inc. | $237.76B | Mega cap | +60.12% |
| TMO | Thermo Fisher Scientific Inc. | $234.31B | Mega cap | +30.17% |
| TN8.DE | Thermo Fisher Scientific Inc. | $234.00B | Mega cap | +29.67% |
| TMOS34.SA | Thermo Fisher Scientific Inc. | $231.47B | Mega cap | +22.22% |
| NVO.WA | Novo Nordisk A/S | $212.23B | Mega cap | −9.22% |
| NOVO-B.CO | Novo Nordisk A/S | $210.20B | Mega cap | −11.26% |
| NOV.DE | Novo Nordisk A/S | $209.27B | Mega cap | +15.22% |
| N1VO34.SA | Novo Nordisk A/S | $208.90B | Mega cap | −17.86% |
| NVO | Novo Nordisk A/S | $208.63B | Mega cap | −13.32% |
| ABL.DE | Abbott Laboratories | $200.44B | Mega cap | −10.02% |
| AVTR | Avantor, Inc. | $9.81B | Mid cap | +9.93% |
| PTGX | Protagonist Therapeutics, Inc. | $9.80B | Mid cap | +146.62% |
| NUVL | Nuvalent Inc | $9.79B | Mid cap | +62.83% |
| BIO-B | Bio-Rad Laboratories, Inc. | $9.77B | Mid cap | +47.78% |
| OSCR | Oscar Health, Inc. | $9.55B | Mid cap | +83.55% |
| TWST | Twist Bioscience Corporation | $9.41B | Mid cap | +451.89% |
| DEMANT.CO | Demant A/S | $9.36B | Mid cap | +17.12% |
| WDH1.DE | Demant A/S | $9.33B | Mid cap | −5.53% |
| KRK.WA | Krka, d. d. | $9.20B | Mid cap | +30.59% |
| PCVX | Vaxcyte, Inc. | $9.09B | Mid cap | +99.97% |
| IMVT | Immunovant, Inc. | $9.07B | Mid cap | +189.13% |
| QGEN | Qiagen N.V. | $9.01B | Mid cap | −9.65% |
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.00B | Mid cap | +179.08% |
| HQY | HealthEquity, Inc. | $8.75B | Mid cap | +18.69% |
| BRKR | Bruker Corporation | $8.69B | Mid cap | +70.56% |
| ATR | AptarGroup, Inc. | $8.60B | Mid cap | −1.89% |
| 4151.T | Kyowa Kirin Co., Ltd. | $8.51B | Mid cap | +4.01% |
| 4523.T | Eisai Co., Ltd. | $8.48B | Mid cap | +7.64% |
| TGTX | TG Therapeutics, Inc. Common Stock | $8.42B | Mid cap | +92.61% |
| TXG | 10x Genomics, Inc. | $8.37B | Mid cap | +358.35% |
| RHC.AX | Ramsay Health Care Limited | $8.27B | Mid cap | +50.11% |
| ALKS | Alkermes plc | $8.25B | Mid cap | +68.07% |
| SYRE | Spyre Therapeutics, Inc. | $8.13B | Mid cap | +446.12% |
| RYTM | Rhythm Pharmaceuticals, Inc. | $7.78B | Mid cap | +9.35% |
| CAI | Caris Life Sciences, Inc. | $7.58B | Mid cap | −29.83% |
| 4528.T | Ono Pharmaceutical Co., Ltd. | $7.39B | Mid cap | +54.43% |
| SRRK | Scholar Rock Holding Corporation | $7.31B | Mid cap | +74.18% |
| 6869.T | Sysmex Corporation | $7.28B | Mid cap | +3.66% |
| HNGE | Hinge Health, Inc. | $7.25B | Mid cap | +56.66% |
| CHE | Chemed Corporation | $7.11B | Mid cap | +20.79% |
| PACS | PACS Group, Inc. | $7.03B | Mid cap | +274.28% |
| GETI-B.ST | Getinge AB (publ) | $7.01B | Mid cap | +20.89% |
| HIMS | Hims & Hers Health, Inc. | $6.96B | Mid cap | −32.22% |
| CGON | CG Oncology, Inc. | $6.95B | Mid cap | +196.15% |
| ERAS | Erasca, Inc. | $6.70B | Mid cap | +1112.03% |
| 7747.T | Asahi Intecc Co., Ltd. | $6.68B | Mid cap | +53.99% |
| LNTH | Lantheus Holdings, Inc. | $6.58B | Mid cap | +77.38% |
| ORKA | Oruka Therapeutics, Inc. | $6.58B | Mid cap | +555.07% |
| HLUN-B.CO | H. Lundbeck A/S | $6.47B | Mid cap | +8.99% |
| 3088.T | MatsukiyoCocokara & Co. | $6.45B | Mid cap | −14.74% |
| HLUN-A.CO | H. Lundbeck A/S | $6.40B | Mid cap | +29.71% |
| BLTE | Belite Bio, Inc | $6.31B | Mid cap | +144.07% |
| LQDA | Liquidia Corporation | $6.31B | Mid cap | +154.86% |
| CNTA | Centessa Pharmaceuticals plc | $6.27B | Mid cap | +143.24% |
| AMRX | Amneal Pharmaceuticals, Inc. | $6.27B | Mid cap | +92.20% |
| TVTX | Travere Therapeutics, Inc. | $6.24B | Mid cap | +284.86% |
| XENE | Xenon Pharmaceuticals Inc. | $6.18B | Mid cap | +64.11% |
| BLCO.TO | Bausch + Lomb Corporation | $6.18B | Mid cap | +19.34% |
| BLCO | Bausch + Lomb Corporation | $6.16B | Mid cap | +18.56% |
| DNTH | Dianthus Therapeutics, Inc. | $6.13B | Mid cap | +356.93% |
| STVN | Stevanato Group S.p.A. | $6.11B | Mid cap | −0.09% |
| KNSA | Kiniksa Pharmaceuticals International, plc | $6.05B | Mid cap | +133.47% |
| RDNT | RadNet, Inc. | $6.05B | Mid cap | +7.27% |
| CTEC.L | Convatec Group PLC | $6.01B | Mid cap | −1.95% |
| T1FX34.SA | Teleflex Incorporated | $6.00B | Mid cap | +0.29% |
| MIRM | Mirum Pharmaceuticals, Inc. | $5.98B | Mid cap | +31.96% |
| DFTX | Definium Therapeutics, Inc. | $5.88B | Mid cap | +344.37% |
| TFX | Teleflex Incorporated | $5.88B | Mid cap | +8.06% |
| LGND | Ligand Pharmaceuticals Incorporated | $5.74B | Mid cap | +80.92% |
| CRSP | CRISPR Therapeutics AG | $5.73B | Mid cap | +10.65% |
| SECT-B.ST | Sectra AB (publ) | $5.63B | Mid cap | −17.02% |
| SHC | Sotera Health Company | $5.58B | Mid cap | +18.42% |
| MMSI | Merit Medical Systems, Inc. | $5.44B | Mid cap | −0.28% |
| ACAD | ACADIA Pharmaceuticals Inc. | $5.07B | Mid cap | +11.33% |
| DYN | Dyne Therapeutics, Inc. | $4.92B | Mid cap | +93.26% |
| HAE | Haemonetics Corporation | $4.85B | Mid cap | +93.71% |
| EWTX | Edgewise Therapeutics, Inc. | $4.80B | Mid cap | +207.13% |
| LFST | LifeStance Health Group, Inc. | $4.69B | Mid cap | +121.31% |
| 128940.KS | Hanmi Pharm. Co., Ltd. | $4.63B | Mid cap | +66.34% |
| HIK.L | Hikma Pharmaceuticals PLC | $4.61B | Mid cap | −9.62% |
| BLLN | BillionToOne, Inc. | $4.54B | Mid cap | −11.68% |
| ICUI | ICU Medical, Inc. | $4.49B | Mid cap | +41.83% |
| NVST | Envista Holdings Corporation | $4.47B | Mid cap | +30.89% |
| ELVN | Enliven Therapeutics, Inc. | $4.46B | Mid cap | +194.32% |
| CON | Concentra Group Holdings Parent, Inc. | $4.44B | Mid cap | +50.93% |
| LIVN | LivaNova PLC | $4.41B | Mid cap | +41.56% |
| TNGX | Tango Therapeutics, Inc. | $4.29B | Mid cap | +269.13% |
| RLAY | Relay Therapeutics, Inc. | $4.26B | Mid cap | +445.10% |
| HTFL | Heartflow, Inc. | $4.26B | Mid cap | +40.79% |
| ITGR | Integer Holdings Corporation | $4.25B | Mid cap | +15.84% |
| INDV | Indivior Pharmaceuticals, Inc. | $4.23B | Mid cap | +47.06% |
| ADPT | Adaptive Biotechnologies Corporation | $4.18B | Mid cap | +101.70% |
| ANN.AX | Ansell Limited | $4.17B | Mid cap | +18.41% |
| AMLX | Amylyx Pharmaceuticals, Inc. | $4.13B | Mid cap | +292.38% |
| 1SXP.DE | SCHOTT Pharma AG & Co. KGaA | $4.08B | Mid cap | +1.26% |
| IDYA | IDEAYA Biosciences, Inc. | $4.01B | Mid cap | +66.32% |
| VKTX | Viking Therapeutics, Inc. | $4.01B | Mid cap | +29.15% |
| DNLI | Denali Therapeutics Inc. | $3.98B | Mid cap | +57.50% |
| ABCL | AbCellera Biologics Inc. | $3.97B | Mid cap | +181.38% |
| RCUS | Arcus Biosciences, Inc. | $3.92B | Mid cap | +191.29% |
| CPRX | Catalyst Pharmaceuticals Inc | $3.85B | Mid cap | +55.97% |
| MCOV-B.ST | Medicover AB (publ) | $3.85B | Mid cap | −8.20% |
| TLX.AX | Telix Pharmaceuticals Limited | $3.82B | Mid cap | +4.88% |
| CAMX.ST | Camurus AB (publ) | $3.79B | Mid cap | −15.35% |
| TLX | Telix Pharmaceuticals Limited | $3.77B | Mid cap | −8.02% |
| 4536.T | Santen Pharmaceutical Co., Ltd. | $3.74B | Mid cap | +21.45% |
| 7459.T | MediPal Holdings Corporation | $3.72B | Mid cap | +13.38% |
| IOVA | Iovance Biotherapeutics, Inc. | $3.66B | Mid cap | +233.88% |
| OGN | Organon & Co. | $3.62B | Mid cap | +50.67% |
| VCYT | Veracyte, Inc. Common Stock | $3.56B | Mid cap | +54.81% |
| GRAL | GRAIL, Inc. | $3.55B | Mid cap | +136.66% |
| QURE | uniQure N.V. | $3.53B | Mid cap | +223.49% |
| NHC | National HealthCare Corporation | $3.53B | Mid cap | +103.83% |
| PLSE | Pulse Biosciences, Inc. | $3.43B | Mid cap | +203.47% |
| IMNM | Immunome, Inc. | $3.34B | Mid cap | +188.94% |
| MRVI | Maravai LifeSciences Holdings, Inc. | $3.30B | Mid cap | +281.97% |
| MBX | MBX Biosciences, Inc. | $3.22B | Mid cap | +366.53% |
| BEAM | Beam Therapeutics Inc. | $3.21B | Mid cap | +79.06% |
| AFX.DE | Carl Zeiss Meditec AG | $3.19B | Mid cap | −24.83% |
| CLDX | Celldex Therapeutics, Inc. | $3.19B | Mid cap | +79.51% |
| IRON | Disc Medicine, Inc. | $3.17B | Mid cap | +37.90% |
| WRBY | Warby Parker Inc. | $3.15B | Mid cap | −3.96% |
| TARS | Tarsus Pharmaceuticals, Inc. | $3.10B | Mid cap | +22.19% |
| ALMS | Alumis Inc. | $3.06B | Mid cap | +380.08% |
| BIOA-B.ST | BioArctic AB (publ) | $3.00B | Mid cap | +12.31% |
| AVAH | Aveanna Healthcare Holdings Inc. | $2.97B | Mid cap | +73.50% |
| ZLAB | Zai Lab Limited | $2.92B | Mid cap | −20.06% |
| ACHC | Acadia Healthcare Company, Inc. | $2.85B | Mid cap | +37.81% |
| B72.DE | AtaiBeckley Inc. | $2.79B | Mid cap | +59.69% |
| SLS | SELLAS Life Sciences Group, Inc. | $2.77B | Mid cap | +615.10% |
| NRIX | Nurix Therapeutics, Inc. | $2.77B | Mid cap | +179.69% |
| VRDN | Viridian Therapeutics, Inc. | $2.75B | Mid cap | +30.71% |
| ATAI | AtaiBeckley Inc. | $2.74B | Mid cap | +61.71% |
| AMBU-B.CO | Ambu A/S | $2.69B | Mid cap | −19.13% |
| WGS | GeneDx Holdings Corp. | $2.69B | Mid cap | −30.11% |
| AXGN | AxoGen, Inc. Common Stock | $2.68B | Mid cap | +219.58% |
| PGEN | Precigen, Inc. | $2.65B | Mid cap | +61.66% |
| CDNA | CareDx, Inc. | $2.64B | Mid cap | +283.45% |
| RARE | Ultragenyx Pharmaceutical Inc. | $2.61B | Mid cap | −12.10% |
| PHVS | Pharvaris N.V. | $2.60B | Mid cap | +55.59% |
| BHVN | Biohaven Ltd. | $2.56B | Mid cap | +8.65% |
| TRVI | Trevi Therapeutics, Inc. | $2.55B | Mid cap | +124.00% |
| BV3.DE | Bavarian Nordic A/S | $2.55B | Mid cap | +15.65% |
| NEOG | Neogen Corporation | $2.54B | Mid cap | +103.83% |
| RAPP | Rapport Therapeutics, Inc. | $2.52B | Mid cap | +250.70% |
| NKTR | Nektar Therapeutics | $2.52B | Mid cap | +151.95% |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.51B | Mid cap | +15.38% |
| CURA.TO | Curaleaf Holdings, Inc. | $2.51B | Mid cap | +197.74% |
| BAVA.CO | Bavarian Nordic A/S | $2.51B | Mid cap | −7.97% |
| KOD | Kodiak Sciences Inc. | $2.48B | Mid cap | +321.09% |
| DRW3.DE | Drägerwerk AG & Co. KGaA | $2.45B | Mid cap | +70.53% |
| ATRC | AtriCure, Inc. | $2.45B | Mid cap | +29.14% |
| NUVB | Nuvation Bio Inc. | $2.44B | Mid cap | +135.93% |
| 3549.T | Kusuri No Aoki Holdings Co., Ltd. | $2.44B | Mid cap | +5.23% |
| BHC | Bausch Health Companies Inc. | $2.43B | Mid cap | −10.45% |
| BHC.TO | Bausch Health Companies Inc. | $2.43B | Mid cap | −9.88% |
| ONT.L | Oxford Nanopore Technologies plc | $2.41B | Mid cap | −2.24% |
| OCUL | Ocular Therapeutix, Inc. | $2.37B | Mid cap | −12.58% |
| GRDN | Guardian Pharmacy Services, Inc. | $2.36B | Mid cap | +45.50% |
| 009420.KS | Hanall Biopharma Co., Ltd. | $2.36B | Mid cap | +112.62% |
| UFPT | UFP Technologies, Inc. | $2.36B | Mid cap | +41.94% |
| DMP.DE | Dermapharm Holding SE | $2.31B | Mid cap | +27.27% |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.31B | Mid cap | +4.23% |
| BFLY | Butterfly Network, Inc. | $2.30B | Mid cap | +450.32% |
| NEO | NeoGenomics, Inc. | $2.26B | Mid cap | +145.34% |
| NBTX | Nanobiotix S.A. | $2.26B | Mid cap | +394.99% |
| CLOV | Clover Health Investments, Corp. | $2.26B | Mid cap | +57.99% |
| MSB.AX | Mesoblast Limited | $2.25B | Mid cap | +1.03% |
| ADUS | Addus HomeCare Corporation | $2.25B | Mid cap | +4.50% |
| URGN | UroGen Pharma Ltd. | $2.25B | Mid cap | +135.11% |
| MESO | Mesoblast Limited | $2.23B | Mid cap | +4.47% |
| PVLA | Palvella Therapeutics, Inc. | $2.22B | Mid cap | +173.39% |
| AUPH | Aurinia Pharmaceuticals Inc. | $2.20B | Mid cap | +36.58% |
| EKTA-B.ST | Elekta AB (publ) | $2.20B | Mid cap | +26.10% |
| MD | Pediatrix Medical Group, Inc. | $2.19B | Mid cap | +56.87% |
| EXE.TO | Extendicare Inc. | $2.18B | Mid cap | +146.56% |
| VCEL | Vericel Corporation | $2.17B | Mid cap | +18.25% |
| ZBIO | Zenas BioPharma, Inc. | $2.15B | Mid cap | +97.73% |
| CLOV34.SA | Clover Health Investments, Corp. | $2.15B | Mid cap | +45.23% |
| STOK | Stoke Therapeutics, Inc. | $2.14B | Mid cap | +71.45% |
| XNCR | Xencor, Inc. Common Stock | $2.11B | Mid cap | +254.61% |
| 008930.KS | Hanmi Science Co., Ltd. | $2.11B | Mid cap | +2.80% |
| ZYME | Zymeworks Inc. | $2.10B | Mid cap | +96.28% |
| NVCR | NovoCure Limited | $2.08B | Mid cap | +50.21% |
| ALIF-B.ST | AddLife AB (publ) | $2.08B | Mid cap | −7.20% |
| SRPT | Sarepta Therapeutics, Inc. | $2.06B | Mid cap | +7.69% |
| NANO.PA | Nanobiotix S.A. | $2.05B | Mid cap | +358.21% |
| PRGO | Perrigo Company plc | $2.05B | Mid cap | −36.05% |
| SEM | Select Medical Holdings Corp | $2.05B | Mid cap | +28.14% |
| AGIO | Agios Pharmaceuticals, Inc. Common Stock | $2.03B | Mid cap | −13.45% |
| CMPS | COMPASS Pathways plc | $2.02B | Mid cap | +209.53% |
| 6960.T | Fukuda Denshi Co., Ltd. | $2.02B | Mid cap | +79.12% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.